Fig 2. No association between SARS-CoV-2 neutralizing antibodies and fatal outcome in critically ill COVID-19 patients.

(A-C) Frequency of B cells (A) CD27⁺CD38⁺ plasmablasts (B) and Ki-67⁺ proliferating B cells (C). (D) Log₁₀ of the reciprocal plasma dilution that neutralized 50% of SARS-CoV-2 spike protein-expressing pseudovirus. 50% Inhibitory concentration (IC50). (E-F) Frequency of Ki-67⁺ B cells (E) and Log₁₀ of the reciprocal plasma dilution that neutralized 50% of SARS-CoV-2 spike protein-expressing pseudovirus (F) with critically ill COVID-19 patients stratified by survival. Median ± 95% CI are shown. (A to C) Kruskal-Wallis tests with Dunn’s multiple comparison test. (D to F) Mann-Whitney U-test.